ARTICLE | Company News
FDA approves Tesaro's Varubi for CINV
September 3, 2015 12:42 AM UTC
Tesaro Inc. (NASDAQ:TSRO) said FDA approved an NDA for Varubi rolapitant ( SCH 619734) in combination with other antiemetic agents to prevent chemotherapy-induced nausea and vomiting (CINV) in adults. The company plans to launch Varubi in 4Q15. Spokesperson Jennifer Davis declined to disclose the drug's price.
Tesaro has exclusive, worldwide rights to the oral neurokinin 1 (NK1) substance P receptor ( TACR1) antagonist from Opko Health Inc. (NYSE:OPK; Tel Aviv:OPK). ...